7MM Parkinson’s disease pipeline focuses on disease-modifying agents

There are a total of 93 products in Phase I-III development for PD treatment.

The Parkinson’s disease (PD) therapeutic landscape, which is heavily genericised, shows a growing focus on neuroprotective and disease-modifying therapies (DMTs) across the seven major markets (7MM), said GlobalData.

The report revealed that there are a total of 93 products in Phase I-III development within the 7MM for the treatment of PD, with 66% of these being prospective neuroprotective agents or DMTs.

These investigational agents aim to slow disease progression by targeting mechanisms like alpha-synuclein aggregation and neuroinflammation, said Lorraine Palmer, Pharma Analyst at GlobalData.

“26% of the pipeline DMTs in the pipeline target alpha-synuclein aggregation,” Palmer said.

Non-motor symptoms are also a key focus, with 18% of the pipeline classified as ‘other antiparkinsonian agents,’ which emphasises symptom management beyond the core motor symptoms.

“The distribution of the 93 pipeline agents in the 7MM underscores a strong emphasis on neuroprotective and disease-modifying treatments.” the analyst added.

*7MM countries- France, Germany, Italy, Spain, the UK, the US, and Japan.